Ocular Therapeutix, Inc (OCUL) · Oct 16, 2026 · Exec change
CSO departure
Ocular Therapeutix loses its chief strategy officer as AXPAXLI approaches a planned NDA submission, creating a fresh strategic leadership gap.
Ocular Therapeutix is transitioning from a DEXTENZA commercial base toward a retina-focused growth story led by AXPAXLI, with the company targeting a U.S. NDA submission for wet AMD in the fourth quarter of 2026.
The strategic leadership seat is now vacant at a sensitive point in that transition. Chief Strategy Officer Sanjay Nayak is leaving effective October 16, 2026 to become CEO of a private company. 〔0〕
This is more consequential than a routine executive reshuffle, but not a pipeline setback by itself. Nayak is not the CEO or chief development officer, and the filing gives no indication that AXPAXLI’s clinical, regulatory, or NDA plans have changed. The immediate effect is a newly created strategic-execution gap just as the company moves toward a major regulatory milestone; no successor or transition plan is disclosed.
Bottom line: The filing adds leadership uncertainty to an already milestone-driven AXPAXLI story, without changing the program’s stated regulatory trajectory. It matters, but mainly as an execution and continuity issue rather than evidence of a program setback.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!